SCHEMBL4861629

SCHEMBL4861629

CSc1ccc(C(N)=Nc2ccc(C(C)C)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 7/20 0.54
NOS1 P29475 7/20 0.54
NOS2 P35228 4/20 0.49
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
PRSS1 P07477 1/20 0.46
ACR P10323 1/20 0.46
SCN5A Q14524 1/20 0.45
SCN2A Q99250 1/20 0.45
HTT P42858 1/20 0.43
CYP2D6 P10635 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4856119 0.84 NOS3 (0.58) NOS3NOS1NOS2ALDH1A1SMN1; SMN2
SCHEMBL4864124 0.84 NOS3 (0.58) NOS3NOS1NOS2ALDH1A1SMN1; SMN2
SCHEMBL4853071 0.82 CYP2D6 (0.64) NOS3NOS1NOS2SMN1; SMN2GRIN2D
SCHEMBL4854767 0.81 NOS1 (0.58) NOS3NOS1NOS2ALDH1A1SMN1; SMN2
SCHEMBL4857038 0.81 NOS1 (0.58) NOS3NOS1NOS2ALDH1A1SMN1; SMN2
SCHEMBL4852965 0.81 NOS1 (0.58) NOS3NOS1SMN1; SMN2GRIN2DGRIN3B
SCHEMBL4857014 0.80 MEN1 (0.66) NOS3NOS1NOS2GRIN1GRIN2B
SCHEMBL4860016 0.78 NOS3 (0.54) NOS3NOS1ALDH1A1PRSS1ACR
SCHEMBL4861886 0.78 NOS3 (0.54) NOS3NOS1NOS2PRSS1ACR
SCHEMBL4854660 0.78 NOS1 (0.54) NOS3NOS1NOS2SMN1; SMN2GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP NOS3 3830/4885NOS1 3074/4885NOS2 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.